Right. I was only pointing to Phase IIb/III trials currently underway based on the Chairman's interview. That's all.
On the 60% to 70% the statement by itself shows huge confidence. I've not seen any top executive/management of a bio-tech company sticking out his/her neck to say this: probability of the FDA approval is 60% to 70%. Not many anyway.